937 results match your criteria prodromal parkinson's


Timing matters: Otological symptoms and Parkinson's disease.

Parkinsonism Relat Disord 2021 Jul 29;90:23-26. Epub 2021 Jul 29.

Department of Neurology, James J. and Joan A. Gardner Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH, USA. Electronic address:

Introduction: Otological symptoms contribute to the disability of established Parkinson's disease (PD). We sought to evaluate whether prodromal onset may affect PD progression.

Methods: A retrospective cohort design was used to compare time to advanced disease, defined as a Hoehn & Yahr stage ≥3 in consecutive PD patients with history of auditory and/or vestibular symptoms appearing before versus after PD onset. Read More

View Article and Full-Text PDF

Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson's Disease Subtypes.

J Parkinsons Dis 2021 Jul 28. Epub 2021 Jul 28.

Aarhus University Hospital, Nuclear Medicine and PET Centre, Aarhus, Denmark.

Background: We have hypothesized that Parkinson's disease (PD) comprises two subtypes. Brain-first, where pathogenic α-synuclein initially forms unilaterally in one hemisphere leading to asymmetric nigrostriatal degeneration, and body-first with initial enteric pathology, which spreads through overlapping vagal innervation leading to more symmetric brainstem involvement and hence more symmetric nigrostriatal degeneration. Isolated REM sleep behaviour disorder has been identified as a strong marker of the body-first type. Read More

View Article and Full-Text PDF

Alpha-Synuclein Pathology Coincides With Increased Number of Early Stage Neural Progenitors in the Adult Hippocampus.

Front Cell Dev Biol 2021 7;9:691560. Epub 2021 Jul 7.

Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine Hannover, Hanover, Germany.

Alpha-synuclein pathology driven impairment in adult neurogenesis was proposed as a potential cause of, or at least contributor to, memory impairment observed in both patients and animal models of Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). Mice overexpressing wild-type alpha-synuclein under the Thy-1 promoter (Thy1-aSyn, line 61) uniquely replicate early cognitive deficits together with multiple other characteristic motor and non-motor symptoms, alpha-synuclein pathology and dopamine loss. Here we report overt intracellular accumulation of phosphorylated alpha-synuclein in the hippocampus of these transgenic mice. Read More

View Article and Full-Text PDF

Probing the Pre-diagnostic Phase of Parkinson's Disease in Population-Based Studies.

Front Neurol 2021 1;12:702502. Epub 2021 Jul 1.

Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, Netherlands.

Parkinson's disease covers a wide spectrum of symptoms, ranging from early non-motor symptoms to the characteristic bradykinesia, tremor and rigidity. Although differences in the symptomatology of Parkinson's disease are increasingly recognized, there is still a lack of insight into the heterogeneity of the pre-diagnostic phase of Parkinson's disease. In this perspective, we highlight three aspects regarding the role of population-based studies in providing new insights into the heterogeneity of pre-diagnostic Parkinson's disease. Read More

View Article and Full-Text PDF

Clinical and Dopamine Depletion Patterns in Hyposmia- and Dysautonomia-Dominant Parkinson's Disease.

J Parkinsons Dis 2021 Jul 10. Epub 2021 Jul 10.

Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea.

Background: Olfactory or autonomic dysfunction is one of the earliest prodromal symptoms of Parkinson's disease (PD). It has not been investigated whether PD patients have different phenotypes depending on the presence of these prodromal symptoms.

Objective: To investigate whether hyposmia-dominant and dysautonomia-dominant patients with early PD have different clinical manifestations and nigrostriatal degeneration. Read More

View Article and Full-Text PDF

Comprehensive Serum Lipidomics for Detecting Incipient Dementia in Parkinson's Disease.

J Proteome Res 2021 Jul 12. Epub 2021 Jul 12.

Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2R3, Canada.

While a number of methods are available for analyzing lipids, unbiased untargeted lipidomics with high coverage remains a challenge. In this work, we report a study of isotope-standard-assisted liquid chromatography mass spectrometry lipidomics of serum for biomarker discovery. We focus on Parkinson's disease (PD), a neurodegenerative disorder that often progresses to dementia. Read More

View Article and Full-Text PDF

Parkinson's Disease and the Gut: Symptoms, Nutrition, and Microbiota.

J Parkinsons Dis 2021 Jul 7. Epub 2021 Jul 7.

Faculty of Health and Medical Sciences, University of East Anglia, Norwich Research Park, Norwich, United Kingdom.

Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide, characterized by symptoms of bradykinesia, rigidity, postural instability, and tremor. Recently, there has been a growing focus on the relationship between the gut and the development of PD. Emerging to the forefront, an interesting concept has developed suggesting that the initial pathophysiological changes occur in the gastrointestinal tract before changes are seen within the brain. Read More

View Article and Full-Text PDF

Prodromal and advanced non-motor features of Parkinson's disease.

Authors:
Peter Kempster

BMJ Neurol Open 2021 21;3(1):e000168. Epub 2021 Jun 21.

Neurosciences Department, Monash Medical Centre, Clayton, Victoria, Australia.

View Article and Full-Text PDF

Cognitive function in men with non-motor features of Parkinson's disease.

BMJ Neurol Open 2021 21;3(1):e000112. Epub 2021 Jun 21.

Departmet of Epidemiology, Harvard University T H Chan School of Public Health, Boston, Massachusetts, USA.

Objective: Subtle cognitive deficits can occur during the prodromal phase of Parkinson's disease (PD), commonly in conjunction with hyposmia. However, little is known about the association between cognitive function and other features suggestive of prodromal PD. We evaluated the association of non-motor prodromal PD features, including hyposmia, constipation and probable REM sleep behaviour disorder (pRBD), with objective measures of cognitive function and self-reported cognitive decline. Read More

View Article and Full-Text PDF

Aberrant cerebral perfusion pattern in amnestic mild cognitive impairment and Parkinson's disease with mild cognitive impairment: a comparative arterial spin labeling study.

Quant Imaging Med Surg 2021 Jul;11(7):3082-3097

Department of Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Background: Mild cognitive impairment (MCI) has been defined as the prodromal stage of Alzheimer's disease and Parkinson's disease (PD) with dementia. We investigated the differences in regional perfusion properties among MCI subtypes and healthy control (HC) subjects by using arterial spin labeling (ASL).

Methods: Regional normalized CBF (z-CBF) and CBF-connectivity were analyzed from ASL data in 44 amnestic MCI (aMCI) patients, 42 PD-MCI patients, and 50 matched HC participants. Read More

View Article and Full-Text PDF

A convolutional-recurrent neural network approach to resting-state EEG classification in Parkinson's disease.

J Neurosci Methods 2021 Jul 6;361:109282. Epub 2021 Jul 6.

Pacific Parkinson's Research Centre, University of British Columbia, Canada; Department of Medicine (Neurology), University of British Columbia, Canada. Electronic address:

Background: Parkinson's disease (PD) is expected to become more common, particularly with an aging population. Diagnosis and monitoring of the disease typically rely on the laborious examination of physical symptoms by medical experts, which is necessarily limited and may not detect the prodromal stages of the disease.

New Method: We propose a lightweight (~20 K parameters) deep learning model to classify resting-state EEG recorded from people with PD and healthy controls (HC). Read More

View Article and Full-Text PDF

An Update on Medical and Surgical Treatments of Parkinson's Disease.

Aging Dis 2021 Jul 1;12(4):1021-1035. Epub 2021 Jul 1.

1Department of Neurology, Marshall University School of Medicine, Huntington, WV 25701, USA.

Parkinson's disease (PD) is characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta and other neuronal populations. The worldwide prevalence of PD is over 7 million and has been increasing more rapidly than many other neurodegenerative disorders. PD symptoms can be broadly divided into motor (slowness, stiffness, tremor) and non-motor symptoms (such as depression, dementia, psychosis, orthostatic hypotension). Read More

View Article and Full-Text PDF

[Non-motor symptoms in Parkinson's disease].

Ugeskr Laeger 2021 07;183(27)

Parkinson's disease is a neurodegenerative movement disorder with a broad spectrum of both motor- and non-motor symptoms. A new top-down model for pathogenesis has recently been suggested, supporting the hypothesis on onset of prodromal non-motor features several years before motor symptoms. Non-motor symptoms have a high prevalence and a substantial effect on quality of life and disease burden. Read More

View Article and Full-Text PDF

REM sleep without atonia and nocturnal body position in prediagnostic Parkinson's disease.

Sleep Med 2021 Jun 17;84:308-316. Epub 2021 Jun 17.

Department of Neurology, Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium; Faculty of Medicine and Health Sciences, Translational Neurosciences, University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium; Born-Bunge Institute, University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium. Electronic address:

Background: Sleep disturbances are features of Parkinson's disease (PD), that can already occur before PD diagnosis. The most investigated prodromal PD sleep disorder is REM sleep behavior disorder (RBD). The relation between other polysomnographic (PSG) alterations and the prediagnostic stages of PD, however, is less clear. Read More

View Article and Full-Text PDF

Lewy Body Dementias: A Coin with Two Sides?

Behav Sci (Basel) 2021 Jun 22;11(7). Epub 2021 Jun 22.

Department of Neurology, Clínica Universidad de Navarra, 28027 Madrid, Spain.

Lewy body dementias (LBDs) consist of dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), which are clinically similar syndromes that share neuropathological findings with widespread cortical Lewy body deposition, often with a variable degree of concomitant Alzheimer pathology. The objective of this article is to provide an overview of the neuropathological and clinical features, current diagnostic criteria, biomarkers, and management of LBD. Literature research was performed using the PubMed database, and the most pertinent articles were read and are discussed in this paper. Read More

View Article and Full-Text PDF

Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson's Disease.

Int J Mol Sci 2021 Jun 17;22(12). Epub 2021 Jun 17.

Laboratory Experimental Neurophysiology, IRCCS San Raffaele Pisana, 00166 Rome, Italy.

Parkinson's disease (PD) is considered the most common disorder of synucleinopathy, which is characterised by intracellular inclusions of aggregated and misfolded α-synuclein (α-syn) protein in various brain regions, and the loss of dopaminergic neurons. During the early prodromal phase of PD, synaptic alterations happen before cell death, which is linked to the synaptic accumulation of toxic α-syn specifically in the presynaptic terminals, affecting neurotransmitter release. The oligomers and protofibrils of α-syn are the most toxic species, and their overexpression impairs the distribution and activation of synaptic proteins, such as the SNARE complex, preventing neurotransmitter exocytosis and neuronal synaptic communication. Read More

View Article and Full-Text PDF

Behavioral Phenotyping in a Murine Model of -Associated Parkinson Disease.

Int J Mol Sci 2021 Jun 25;22(13). Epub 2021 Jun 25.

Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Mutations in , the gene encoding glucocerebrosidase, are common genetic risk factors for Parkinson disease (PD). While the mechanism underlying this relationship is unclear, patients with -associated PD often have an earlier onset and faster progression than idiopathic PD. Previously, we modeled -associated PD by crossing haploinsufficient mice with mice overexpressing a human mutant α-synuclein transgene (), observing an earlier demise, shorter life span and faster symptom progression, although behavioral testing was not performed. Read More

View Article and Full-Text PDF

Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical Management.

Brain Sci 2021 Jun 23;11(7). Epub 2021 Jun 23.

Centre Hospitalo-Universitaire de Rouen, INSERM UMR 1073, CIC-CRB 1404, 76000 Rouen, France.

Patients with Parkinson disease (PD) experience a range of non-motor symptoms, including gastrointestinal symptoms. These symptoms can be present in the prodromal phase of the disease. Recent advances in pathophysiology reveal that α-synuclein aggregates that form Lewy bodies and neurites, the hallmark of PD, are present in the enteric nervous system and may precede motor symptoms. Read More

View Article and Full-Text PDF

Slow Motion Analysis of Repetitive Tapping (SMART) Test: Measuring Bradykinesia in Recently Diagnosed Parkinson's Disease and Idiopathic Anosmia.

J Parkinsons Dis 2021 Jun 22. Epub 2021 Jun 22.

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

Background: Bradykinesia is the defining motor feature of Parkinson's disease (PD). There are limitations to its assessment using standard clinical rating scales, especially in the early stages of PD when a floor effect may be observed.

Objective: To develop a quantitative method to track repetitive tapping movements and to compare people in the early stages of PD, healthy controls, and individuals with idiopathic anosmia. Read More

View Article and Full-Text PDF

The neuromicrobiology of Parkinson's disease: A unifying theory.

Ageing Res Rev 2021 Jun 23;70:101396. Epub 2021 Jun 23.

CNC-Center for Neuroscience and Cell Biology and CIBB-Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal; Institute of Cellular and Molecular Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal. Electronic address:

Recent evidence confirms that PD is indeed a multifactorial disease with different aetiologies and prodromal symptomatology that likely depend on the initial trigger. New players with important roles as triggers, facilitators and aggravators of the PD neurodegenerative process have re-emerged in the last few years, the microbes. Having evolved in association with humans for ages, microbes and their products are now seen as fundamental regulators of human physiology with disturbances in their balance being increasingly accepted to have a relevant impact on the progression of disease in general and on PD in particular. Read More

View Article and Full-Text PDF

α-Synuclein Responses in the Laterodorsal Tegmentum, the Pedunculopontine Tegmentum, and the Substantia Nigra: Implications for Early Appearance of Sleep Disorders in Parkinson's Disease.

J Parkinsons Dis 2021 Jun 14. Epub 2021 Jun 14.

Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.

Background: Parkinson's disease (PD) is a neurodegenerative disorder associated with insoluble pathological aggregates of the protein α-synuclein. While PD is diagnosed by motor symptoms putatively due to aggregated α-synuclein-mediated damage to substantia nigra (SN) neurons, up to a decade before motor symptom appearance, patients exhibit sleep disorders (SDs). Therefore, we hypothesized that α-synuclein, which can be present in monomeric, fibril, and other forms, has deleterious cellular actions on sleep-control nuclei. Read More

View Article and Full-Text PDF

Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease: clues to early diagnosis and effective treatment.

Arch Pharm Res 2021 Jun 19;44(6):588-604. Epub 2021 Jun 19.

College of Pharmacy and Institute of Pharmaceutical Sciences, CHA University, Pocheon, Gyeonggi-do, 11160, Republic of Korea.

Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by movement dysfunction due to selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. Non-motor symptoms of PD (e.g. Read More

View Article and Full-Text PDF

Prodromal neuroinvasion of pathological α-synuclein in brainstem reticular nuclei and white matter lesions in a model of α-synucleinopathy.

Brain Commun 2021 14;3(2):fcab104. Epub 2021 May 14.

Department of Biomedicine, Danish Research Institute of Translational Neuroscience (DANDRITE), Aarhus University, DK-8000 Aarhus C, Denmark.

Neuropathological observations in neurodegenerative synucleinopathies, including Parkinson disease, implicate a pathological role of α-synuclein accumulation in extranigral sites during the prodromal phase of the disease. In a transgenic mouse model of peripheral-to-central neuroinvasion and propagation of α-synuclein pathology (via hindlimb intramuscular inoculation with exogenous fibrillar α-synuclein: the M83 line, expressing the mutant human Ala53Thr α-synuclein), we studied the development and early-stage progression of α-synuclein pathology in the CNS of non-symptomatic (i.e. Read More

View Article and Full-Text PDF

Alteration of brain structural connectivity in progression of Parkinson's disease: A connectome-wide network analysis.

Neuroimage Clin 2021 Jun 6;31:102715. Epub 2021 Jun 6.

Department of Neurobiology, Neurology and Geriatrics, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Disease, Beijing, China. Electronic address:

Pinpointing the brain dysconnectivity in idiopathic rapid eye movement sleep behaviour disorder (iRBD) can facilitate preventing the conversion of Parkinson's disease (PD) from prodromal phase. Recent neuroimage investigations reported disruptive brain white matter connectivity in both iRBD and PD, respectively. However, the intrinsic process of the human brain structural network evolving from iRBD to PD still remains largely unknown. Read More

View Article and Full-Text PDF

Trend of recognizing depression symptoms and antidepressants use in newly diagnosed Parkinson's disease: Population-based study.

Brain Behav 2021 Jun 14. Epub 2021 Jun 14.

Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.

Objectives: Although depression symptoms are common among patients with Parkinson's disease (PD), the medical literature still reports underrecognition of depression in patients with PD. Our main objective is to examine the trend of depression recognition during the first year of PD diagnosis using large population data.

Methods: We conducted a population-based study of residents in Wales, using the Secure Anonymized Information Linkage (SAIL) Databank. Read More

View Article and Full-Text PDF

Retinal thickness and microvascular pathway in Idiopathic Rapid eye movement sleep behaviour disorder and Parkinson's disease.

Parkinsonism Relat Disord 2021 Jul 6;88:40-45. Epub 2021 Jun 6.

Department of Medical, Surgical Sciences and Advanced Technologies GF Ingrassia, Section of Neurosciences, University of Catania, Catania, CT, Italy. Electronic address:

Introduction: Retinal impairment has previously been described in Parkinson's Disease (PD), also in early stage of disease. Idiopathic Rapid-eye-movement sleep Behavior Disorder (iRBD) is considered the strongest marker in the diagnosis of "Prodromal PD". Thus, we evaluated the thickness of retinal layers and the microvascular retinal pattern in a group of iRBD patients compared to PD and healthy subjects (HCs). Read More

View Article and Full-Text PDF

Sweet or Bland Dreams? Taste Loss in Isolated REM-Sleep Behavior Disorder and Parkinson's Disease.

Mov Disord 2021 Jun 12. Epub 2021 Jun 12.

Sleep Disorders Unit, University Hospital Pitié-Salpêtrière, APHP-Sorbonne, Paris, France.

Background: Hyposmia and isolated REM sleep behavior disorder are well-established features of prodromal Parkinson's disease (PD).

Objectives: The objective of the present study was to evaluate whether taste loss (reported in PD and possibly suggesting brain stem involvement) is present at the isolated REM sleep behavior disorder stage.

Methods: We assessed taste function using the Taste Strip Test (evaluating 4 concentrations of bitter, sweet, sour, and salty) in 44 participants with isolated REM sleep behavior disorder, 19 with PD, and 29 controls. Read More

View Article and Full-Text PDF

Quantifying activities of daily living impairment in Parkinson's disease using the Functional Activities Questionnaire.

Neurol Sci 2021 Jun 10. Epub 2021 Jun 10.

Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany.

Objective: Cognitive-driven activity of daily living (ADL) impairment in Parkinson's disease (PD) is increasingly discussed as prodromal marker for dementia. Diagnostic properties of assessments for this specific ADL impairment are sparsely investigated in PD. The ability of the Functional Activities Questionnaire (FAQ) for differentiating between PD patients with normal cognition and with mild cognitive impairment (PD-MCI), according to informant and self-reports, was examined. Read More

View Article and Full-Text PDF

Gut and brain profiles that resemble pre-motor and early-stage Parkinson's disease in methamphetamine self-administering rats.

Drug Alcohol Depend 2021 Aug 20;225:108746. Epub 2021 May 20.

Department of Pharmacology, Rush University Medical Center, Chicago, IL, 60612, United States; Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL, 60612, United States; Center for Compulsive Behavior and Addiction, Rush University Medical Center, Chicago, IL, 60612, United States.

Introduction: Methamphetamine is a potent psychomotor stimulant, and methamphetamine abusers are up to three times more likely to develop Parkinson's disease (PD) later in life. Prodromal PD may involve gut inflammation and the accumulation of toxic proteins that are transported from the enteric nervous system to the central nervous system to mediate, in part, the degeneration of dopaminergic projections. We hypothesized that self-administration of methamphetamine in rats produces a gut and brain profile that mirrors pre-motor and early-stage PD. Read More

View Article and Full-Text PDF

Premotor antidepressants use differs according to Parkinson's disease subtype: A cohort study.

Parkinsonism Relat Disord 2021 Jun 6;87:137-141. Epub 2021 May 6.

IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy. Electronic address:

Background: Depression is more frequently associated with akinetic-rigid/postural instability gait difficulty subtypes of Parkinson's disease than with tremor-dominant subtype.

Objectives: The aim of the study is to investigate the frequency of exposure to antidepressant drugs, as proxy of depression, before motor onset according to Parkinson's disease subtypes.

Method: Based on a historical cohort design, the exposure to antidepressant drugs before Parkinson's disease motor onset was obtained from the drug prescription database and assessed in the resident population of the Local Healthcare Trust of Bologna (443,117 subjects older than 35 years). Read More

View Article and Full-Text PDF